Search

2024 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, MINNEAPOLIS - [...]

Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in some patients [...]

- National Science Teachers Association, American Academy of Neurology and Red Hat Enterprise Linux were the first conventions to take in the views at the new Bluebird Ballroom. -- DENVER, [...]

AAN, AES and SMFM Collaborate to Develop Updated Guidance MINNEAPOLIS, May 15, 2024 /PRNewswire/ -- A new guideline has been issued to help neurologists and other clinicians determine the best [...]

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven's public offering completed [...]

- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in a platform session at the [...]

Continuous Kesimpta treatment for up to six years showed sustained efficacy in recently diagnosed ([less than or equal to]3 years) treatment-naȯve people living with relapsing multiple sclerosis (RMS) in an [...]

- Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through [...]

ADHERE data show VYVGART (R) Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over [...]

DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual [...]

Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE(TM)) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest [...]

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the 'Company' or 'Aquestive'), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through [...]

NUTLEY, N.J., April 12, 2024 /PRNewswire/ -- Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial [...]

- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine- Seventy percent of subjects achieved[greater [...]

Company's lead pipeline program in IgG sculpting enzymes demonstrates rapid and sustained reduction of IgG levels and ability to address multiple pathogenic mechanisms Preclinical findings support S-1117's differentiated product profile [...]

WATERTOWN, Mass. -- Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will present preclinical data for its pan-immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at [...]

ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART [...]

M2 EQUITYBITES-April 17, 2024-Sanofi presents positive 48-week data on frexalimab for MS (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Wednesday that its CD40L [...]

2024 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, MINNEAPOLIS - [...]

MINNEAPOLIS, Oct. 11, 2023 /PRNewswire/ -- New guidance has been issued for clinicians on the determination of brain death, also known as death by neurologic criteria. A new consensus practice [...]

MINNEAPOLIS, Sept. 21, 2023 /PRNewswire/ -- Do you want to improve your brain health? Neurologists, the experts in brain health, have a plan. The https://c212.net/c/link/?t=0&l=en&o=3975305-1&h=444009446&u=http%3A%2F%2Fwww.aan.com%2F&a=American+Academy+of+Neurology(AAN), the world's largest association of [...]

Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer's disease Preclinical findings with fosgonimeton further elucidate [...]

* PROOF-HD primary endpoint (Unified Huntington Disease Rating Scale-Total Functional Capacity) and the key secondary endpoint (Composite Unified Huntington's Disease Rating Scale) did not reach statistical significance * PROOF-HD marks [...]

M2 PRESSWIRE-April 25, 2023-: NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks [...]

Lead therapeutic candidate for Alzheimer's disease, PMN310, demonstrate d selective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP [...]

-- Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health to better understand holistic health [...]

Eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life WILMINGTON, Del. -- Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid [...]

An oral presentation will highlight findings related to Amprion's ðSyn Seed Amplification Assay and its validation within the landmark Parkinson's Progression Markers Initiative (PPMI) study Amprion leaders will be on [...]

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, [...]

Neurology Qdata Module Will Provide Real-World Evidence from De-Identified Parkinson's Patients in American Academy of Neurology's Axon Registry SAN FRANCISCO, April 21, 2023 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3843418-1&h=112798974&u=https%3A%2F%2Fwww.veranahealth.com%2F&a=Verana+Health -a digital health company [...]

The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previously failed two to four classes of conventional oral [...]